Enhancement of memory and reduction of amyloid plaques in alzheimer\'s disease mouse model using cyclic glycine-proline

Amyloid plaques and neurofibrillary tangles are two of the most important signs that can be used to diagnose Alzheimer's disease (AD), which is a neurodegenerative condition. Animal models, such as APP/PS1 mice, are extremely important for advancing our understanding of the factors that contribute to Alzheimer's disease and evaluating potential treatments. The purpose of this study is to investigate the effects of cyclic glycine-proline (cGP), a stable cyclic dipeptide that originates from glutamate, on spatial memory and the accumulation of amyloid plaque in mice with Alzheimer's disease and Parkinson's disease type 1. In order to evaluate the spatial memory of APP/PS1 mice, the Morris Water Maze was utilised after the mice had been administered cGP. To determine the amount of amyloid plaque in the brain, first the staining was done using thioflavin-S, then imaging was performed, and last the results were quantified. Treatment with cGP resulted in a considerable reduction in the quantity of amyloid plaque and an improvement in spatial memory in mice with APP/PS1 mutations. There was a decline in escape latency times, amyloid plaque numbers, and plaque covering percentages in the cortex and hippocampus. There is evidence to suggest that cGP may have therapeutic potential; in a rat model of Alzheimer's disease, it was found to improve cognitive performance and reduce amyloid pathology. The therapeutic potential of cGP in reducing AD pathology and cognitive impairment is demonstrated by these results.